Dan Wildman is President of Wildman Ventures, LLC., where he serves as a member of the Board of Directors or as a Strategic Advisor for several early-stage organizations and publicly-held companies. Dan applies his expertise and more than four decades of experience to advancing the development program for PanTher’s lead candidate, PTM-101, and selecting and prioritizing other SagittariTM platform products.
Prior to joining PanTher Therapeutics, Dan was at Johnson & Johnson where he led the Digital Surgery Strategy initiative and served as worldwide President of Depuy Synthes Spine, the second-largest spine surgery business in the world. Previously, he served as Worldwide President of Ethicon Biosurgery, where he led the development and commercialization of a novel combination product based on a biomaterial and biologic formulation. The biosurgery business at Ethicon now exceeds $2.0B in revenue and continues to be one of the fastest-growing companies in Johnson & Johnson’s medical device portfolio.